Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
ABIRATERONE + Raloxifene
|
DCSACHY
|
ABIRATERONE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
ABIRATERONE + Raloxifene
|
DCTM6FL
|
ABIRATERONE
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
ABIRATERONE + Raloxifene
|
DCXQMD7
|
ABIRATERONE
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
ABIRATERONE + Raloxifene
|
DCQ14AB
|
ABIRATERONE
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
ABIRATERONE + Raloxifene
|
DCMR12C
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
ABIRATERONE + Raloxifene
|
DCV3SQE
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
ABIRATERONE + Raloxifene
|
DCKNT1B
|
ABIRATERONE
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
ABIRATERONE + Raloxifene
|
DCR5M3A
|
ABIRATERONE
|
Glioma (Cell Line: SF-268)
|
[2] |
|
ABIRATERONE + Raloxifene
|
DCELGUC
|
ABIRATERONE
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
ABIRATERONE + Raloxifene
|
DC8S136
|
ABIRATERONE
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
ABIRATERONE + Raloxifene
|
DCK4XNC
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
ABIRATERONE + Raloxifene
|
DC03WRB
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
ABIRATERONE + Raloxifene
|
DCP5HZ3
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
ABIRATERONE + Raloxifene
|
DCLHYLO
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCJC9CL
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCCLFLB
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DC8A96I
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DC58G3J
|
ABIRATERONE
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCNG3B5
|
ABIRATERONE
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCKWIP2
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCAPMSM
|
ABIRATERONE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCLXAAQ
|
ABIRATERONE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DC7OCPC
|
ABIRATERONE
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCML8JI
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCXDUSI
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCNCBQ9
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCMN4MU
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCYL1PB
|
ABIRATERONE
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCY2CUS
|
ABIRATERONE
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DC8IZGS
|
ABIRATERONE
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCBT4M9
|
ABIRATERONE
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
ABIRATERONE + Raloxifene
|
DCFY0Q5
|
ABIRATERONE
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Amonafide + Raloxifene
|
DCGQMYF
|
Amonafide
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Amonafide + Raloxifene
|
DCLDF6Y
|
Amonafide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Amonafide + Raloxifene
|
DC8NB4H
|
Amonafide
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Amonafide + Raloxifene
|
DCY6XOT
|
Amonafide
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Anastrozole + Raloxifene
|
DCYSUA4
|
Anastrozole
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Anastrozole + Raloxifene
|
DCYK3GT
|
Anastrozole
|
Adenocarcinoma (Cell Line: SW-620)
|
[2] |
|
Anastrozole + Raloxifene
|
DC1GG2N
|
Anastrozole
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Anastrozole + Raloxifene
|
DC3VLOL
|
Anastrozole
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Anastrozole + Raloxifene
|
DC1G579
|
Anastrozole
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[2] |
|
Anastrozole + Raloxifene
|
DC34YIL
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Anastrozole + Raloxifene
|
DCQ21UP
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Anastrozole + Raloxifene
|
DCX4TRB
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Anastrozole + Raloxifene
|
DCT57R0
|
Anastrozole
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Anastrozole + Raloxifene
|
DC94JEL
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[2] |
|
Anastrozole + Raloxifene
|
DCIB4LG
|
Anastrozole
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Anastrozole + Raloxifene
|
DCGEBHS
|
Anastrozole
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Anastrozole + Raloxifene
|
DCJRZMS
|
Anastrozole
|
Prostate carcinoma (Cell Line: PC-3)
|
[2] |
|
Anastrozole + Raloxifene
|
DCD77U9
|
Anastrozole
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Anastrozole + Raloxifene
|
DCY7NWZ
|
Anastrozole
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Arfolitixorin + Raloxifene
|
DCQGL2D
|
Arfolitixorin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Arfolitixorin + Raloxifene
|
DCHLXKK
|
Arfolitixorin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Arfolitixorin + Raloxifene
|
DCIS3Q7
|
Arfolitixorin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Arfolitixorin + Raloxifene
|
DCMN3N2
|
Arfolitixorin
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Arfolitixorin + Raloxifene
|
DCHIIDS
|
Arfolitixorin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
BIO-300 + Raloxifene
|
DC7K5UQ
|
BIO-300
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
BIO-300 + Raloxifene
|
DCH0PXI
|
BIO-300
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
BIO-300 + Raloxifene
|
DCLSGXJ
|
BIO-300
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
BIO-300 + Raloxifene
|
DCHCNQ2
|
BIO-300
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Bleomycin + Raloxifene
|
DC6EZM5
|
Bleomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Bleomycin + Raloxifene
|
DCE02XZ
|
Bleomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Bleomycin + Raloxifene
|
DC19TKM
|
Bleomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Bleomycin + Raloxifene
|
DCNSE01
|
Bleomycin
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Cabazitaxel + Raloxifene
|
DCH2D3K
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Cabazitaxel + Raloxifene
|
DC0U27L
|
Cabazitaxel
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Cabazitaxel + Raloxifene
|
DC2V581
|
Cabazitaxel
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Cabazitaxel + Raloxifene
|
DCQP20D
|
Cabazitaxel
|
Prostate carcinoma (Cell Line: PC-3)
|
[2] |
|
Cabazitaxel + Raloxifene
|
DCAT126
|
Cabazitaxel
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Cabazitaxel + Raloxifene
|
DC69HUX
|
Cabazitaxel
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Cabazitaxel + Raloxifene
|
DCT9NSF
|
Cabazitaxel
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Cabazitaxel + Raloxifene
|
DCBKX6X
|
Cabazitaxel
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Crizotinib + Raloxifene
|
DCUEETS
|
Crizotinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Crizotinib + Raloxifene
|
DCQGOWQ
|
Crizotinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[2] |
|
Crizotinib + Raloxifene
|
DCXA0FE
|
Crizotinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[2] |
|
Crizotinib + Raloxifene
|
DCEKFR2
|
Crizotinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[2] |
|
Crizotinib + Raloxifene
|
DCDOALC
|
Crizotinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Crizotinib + Raloxifene
|
DC2QJ57
|
Crizotinib
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Crizotinib + Raloxifene
|
DCVC52W
|
Crizotinib
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Crizotinib + Raloxifene
|
DC96UYW
|
Crizotinib
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Crizotinib + Raloxifene
|
DCJCXRI
|
Crizotinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Crizotinib + Raloxifene
|
DCRYXSH
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Crizotinib + Raloxifene
|
DCAH9WZ
|
Crizotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Crizotinib + Raloxifene
|
DCEU09E
|
Crizotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[2] |
|
Crizotinib + Raloxifene
|
DCFBD4P
|
Crizotinib
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Crizotinib + Raloxifene
|
DCJVX0Z
|
Crizotinib
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Crizotinib + Raloxifene
|
DC1LJR2
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[2] |
|
Crizotinib + Raloxifene
|
DCY9JKO
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[2] |
|
Crizotinib + Raloxifene
|
DCUUGNF
|
Crizotinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Crizotinib + Raloxifene
|
DCGAYF8
|
Crizotinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Crizotinib + Raloxifene
|
DCWJ2VV
|
Crizotinib
|
Melanoma (Cell Line: UACC-257)
|
[2] |
|
Crizotinib + Raloxifene
|
DC3YNED
|
Crizotinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[2] |
|
Crizotinib + Raloxifene
|
DC7LWEW
|
Crizotinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[2] |
|
Crizotinib + Raloxifene
|
DCX3B2O
|
Crizotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Crizotinib + Raloxifene
|
DC91RMJ
|
Crizotinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
Crizotinib + Raloxifene
|
DCWTTVS
|
Crizotinib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Crizotinib + Raloxifene
|
DCX7FWZ
|
Crizotinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Crizotinib + Raloxifene
|
DCSQG1M
|
Crizotinib
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Crizotinib + Raloxifene
|
DCZROHI
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Crizotinib + Raloxifene
|
DCOBTPY
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Crizotinib + Raloxifene
|
DCQUF1J
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Dacarbazine + Raloxifene
|
DC3MACC
|
Dacarbazine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Dacarbazine + Raloxifene
|
DCUJHZT
|
Dacarbazine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Dacarbazine + Raloxifene
|
DCD2DXE
|
Dacarbazine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Dacarbazine + Raloxifene
|
DCSHZE8
|
Dacarbazine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Dactinomycin + Raloxifene
|
DCNLRGK
|
Dactinomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Dactinomycin + Raloxifene
|
DC59AEV
|
Dactinomycin
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Dactinomycin + Raloxifene
|
DCAC813
|
Dactinomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Dactinomycin + Raloxifene
|
DCJUBME
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Dactinomycin + Raloxifene
|
DCJ19YY
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Dactinomycin + Raloxifene
|
DC7CFFA
|
Dactinomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Dactinomycin + Raloxifene
|
DC9YHJ2
|
Dactinomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Dexrazoxane + Raloxifene
|
DCU4AWS
|
Dexrazoxane
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Dexrazoxane + Raloxifene
|
DCGDUCI
|
Dexrazoxane
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Dexrazoxane + Raloxifene
|
DCH5P1U
|
Dexrazoxane
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Dexrazoxane + Raloxifene
|
DCS9R55
|
Dexrazoxane
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Dexrazoxane + Raloxifene
|
DC77CLZ
|
Dexrazoxane
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Dexrazoxane + Raloxifene
|
DC7TWWJ
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Dexrazoxane + Raloxifene
|
DCZME8D
|
Dexrazoxane
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Dexrazoxane + Raloxifene
|
DCGK6IQ
|
Dexrazoxane
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Dexrazoxane + Raloxifene
|
DCTC615
|
Dexrazoxane
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
DFN-15 + Raloxifene
|
DCI1PGO
|
DFN-15
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
DFN-15 + Raloxifene
|
DCV0O2D
|
DFN-15
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
DFN-15 + Raloxifene
|
DCCLEVY
|
DFN-15
|
Glioma (Cell Line: SF-539)
|
[2] |
|
DFN-15 + Raloxifene
|
DCUOWWW
|
DFN-15
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
DFN-15 + Raloxifene
|
DCXQKWI
|
DFN-15
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
DFN-15 + Raloxifene
|
DCI7CIM
|
DFN-15
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
DFN-15 + Raloxifene
|
DCAHGUO
|
DFN-15
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
DFN-15 + Raloxifene
|
DCYP8M5
|
DFN-15
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Digitoxin + Raloxifene
|
DCKEYE4
|
Digitoxin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Digitoxin + Raloxifene
|
DCTE9U0
|
Digitoxin
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Digitoxin + Raloxifene
|
DCHSNID
|
Digitoxin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Digitoxin + Raloxifene
|
DC7EFJD
|
Digitoxin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Digitoxin + Raloxifene
|
DCE44UW
|
Digitoxin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[2] |
|
Digitoxin + Raloxifene
|
DC5NQ7L
|
Digitoxin
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Digitoxin + Raloxifene
|
DCLFBX1
|
Digitoxin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[2] |
|
Epirubicin + Raloxifene
|
DC5BLYB
|
Epirubicin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Epirubicin + Raloxifene
|
DCPKQK2
|
Epirubicin
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Epirubicin + Raloxifene
|
DCNP7SE
|
Epirubicin
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Epirubicin + Raloxifene
|
DCFB4XA
|
Epirubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Epirubicin + Raloxifene
|
DC765AH
|
Epirubicin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Epirubicin + Raloxifene
|
DCXYC66
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Epirubicin + Raloxifene
|
DCFBPQ4
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Epirubicin + Raloxifene
|
DCRA6JR
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Epirubicin + Raloxifene
|
DC5JB0J
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Epirubicin + Raloxifene
|
DCK3QFE
|
Epirubicin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Epirubicin + Raloxifene
|
DCR5BN8
|
Epirubicin
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Epirubicin + Raloxifene
|
DCA35T3
|
Epirubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Epirubicin + Raloxifene
|
DCZ3HIC
|
Epirubicin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Epirubicin + Raloxifene
|
DC9WT79
|
Epirubicin
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Epirubicin + Raloxifene
|
DCJYQ34
|
Epirubicin
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Epirubicin + Raloxifene
|
DCZAIG7
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Epirubicin + Raloxifene
|
DC1KGEM
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Epirubicin + Raloxifene
|
DC3MYDU
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Epirubicin + Raloxifene
|
DCT5MUT
|
Epirubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Epirubicin + Raloxifene
|
DCOYBGJ
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Epirubicin + Raloxifene
|
DCTRI17
|
Epirubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Epirubicin + Raloxifene
|
DCRN778
|
Epirubicin
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Epirubicin + Raloxifene
|
DCKB5F4
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Epirubicin + Raloxifene
|
DC8MML8
|
Epirubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Epirubicin + Raloxifene
|
DCVLP0T
|
Epirubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Epirubicin + Raloxifene
|
DCR0NA6
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Epirubicin + Raloxifene
|
DCQ2G7Q
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Epirubicin + Raloxifene
|
DC4U5YT
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Epirubicin + Raloxifene
|
DCP6HMO
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Epirubicin + Raloxifene
|
DCQY5WX
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Epirubicin + Raloxifene
|
DCTTKHL
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Epirubicin + Raloxifene
|
DC9BX5L
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Epirubicin + Raloxifene
|
DC7C8D9
|
Epirubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Epirubicin + Raloxifene
|
DCO2Y8M
|
Epirubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Epirubicin + Raloxifene
|
DCBJJ7J
|
Epirubicin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Epirubicin + Raloxifene
|
DCB7XBE
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Epirubicin + Raloxifene
|
DCX76WP
|
Epirubicin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Epirubicin + Raloxifene
|
DCOGO2L
|
Epirubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Epirubicin + Raloxifene
|
DCIGTYZ
|
Epirubicin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Estramustine + Raloxifene
|
DCIGCKR
|
Estramustine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Estramustine + Raloxifene
|
DC2057S
|
Estramustine
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Estramustine + Raloxifene
|
DC8H4VR
|
Estramustine
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Estramustine + Raloxifene
|
DCOF6VT
|
Estramustine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Estramustine + Raloxifene
|
DCVCI00
|
Estramustine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Estramustine + Raloxifene
|
DC1K2L3
|
Estramustine
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Estramustine + Raloxifene
|
DC38CP7
|
Estramustine
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Estramustine + Raloxifene
|
DCROO7R
|
Estramustine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Fludarabine + Raloxifene
|
DCGICB4
|
Fludarabine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Fludarabine + Raloxifene
|
DCKEU93
|
Fludarabine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Fludarabine + Raloxifene
|
DCP3E8S
|
Fludarabine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Fludarabine + Raloxifene
|
DCVSUOD
|
Fludarabine
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Fludarabine + Raloxifene
|
DCCRD94
|
Fludarabine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Fludarabine + Raloxifene
|
DCKZITN
|
Fludarabine
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
FORMESTANE + Raloxifene
|
DC69LGE
|
FORMESTANE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
FORMESTANE + Raloxifene
|
DCBSMMK
|
FORMESTANE
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
FORMESTANE + Raloxifene
|
DCXZIOD
|
FORMESTANE
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
FORMESTANE + Raloxifene
|
DCCE723
|
FORMESTANE
|
Glioma (Cell Line: SF-539)
|
[2] |
|
FORMESTANE + Raloxifene
|
DCJXGER
|
FORMESTANE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[2] |
|
Fulvestrant + Raloxifene
|
DC9C8O9
|
Fulvestrant
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Fulvestrant + Raloxifene
|
DC9JFJ7
|
Fulvestrant
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Fulvestrant + Raloxifene
|
DCKPL8K
|
Fulvestrant
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Fulvestrant + Raloxifene
|
DCHX40Z
|
Fulvestrant
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Fulvestrant + Raloxifene
|
DCBXJJ3
|
Fulvestrant
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[2] |
|
Fulvestrant + Raloxifene
|
DCUUFAA
|
Fulvestrant
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Fulvestrant + Raloxifene
|
DCV89Z4
|
Fulvestrant
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Gefitinib + Raloxifene
|
DC99M1T
|
Gefitinib
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Gefitinib + Raloxifene
|
DCGCXPP
|
Gefitinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Idarubicin + Raloxifene
|
DCND3KG
|
Idarubicin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Idarubicin + Raloxifene
|
DCATEPG
|
Idarubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Idarubicin + Raloxifene
|
DCRFYVV
|
Idarubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Idarubicin + Raloxifene
|
DCDVE4U
|
Idarubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Imatinib + Raloxifene
|
DCG2X15
|
Imatinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Imatinib + Raloxifene
|
DCCTOMT
|
Imatinib
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Imatinib + Raloxifene
|
DCPINYN
|
Imatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Imatinib + Raloxifene
|
DCL5ORZ
|
Imatinib
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DCFF142
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DCFT565
|
Indazole derivative 5
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DCRORZ5
|
Indazole derivative 5
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DCOYVYF
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DCZZLNA
|
Indazole derivative 5
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DCTXNZJ
|
Indazole derivative 5
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DCX1KYU
|
Indazole derivative 5
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DCRFG0B
|
Indazole derivative 5
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCNYUWF
|
Indazole derivative 5
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCEJUMO
|
Indazole derivative 5
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DC165T1
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DC49MQF
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DC5FTAJ
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCDXGEG
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DCVDV3K
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DCG0SN2
|
Indazole derivative 5
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DC7WU5Z
|
Indazole derivative 5
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DCBOEH0
|
Indazole derivative 5
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DCWYMLD
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DCLNSSQ
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DCYKGJ7
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DC0SEVB
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DC4GZS6
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DCYY8VP
|
Indazole derivative 5
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DCVAC2X
|
Indazole derivative 5
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DCUQYGQ
|
Indazole derivative 5
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DC6R3W0
|
Indazole derivative 5
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DC8E7KZ
|
Indazole derivative 5
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Indazole derivative 5 + Raloxifene
|
DC1ONYO
|
Indazole derivative 5
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Lenalidomide + Raloxifene
|
DCPS20I
|
Lenalidomide
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Lenalidomide + Raloxifene
|
DCAHB7Q
|
Lenalidomide
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Lenalidomide + Raloxifene
|
DCEE145
|
Lenalidomide
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Lenalidomide + Raloxifene
|
DC5Y9SW
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Lenalidomide + Raloxifene
|
DC9Q6MU
|
Lenalidomide
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Lenalidomide + Raloxifene
|
DCLOB17
|
Lenalidomide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Lenalidomide + Raloxifene
|
DCT4W2O
|
Lenalidomide
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Letrozole + Raloxifene
|
DCAKM5U
|
Letrozole
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Letrozole + Raloxifene
|
DC16P0C
|
Letrozole
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Letrozole + Raloxifene
|
DC5BRSA
|
Letrozole
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Letrozole + Raloxifene
|
DC9M7WK
|
Letrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Letrozole + Raloxifene
|
DCSSMWC
|
Letrozole
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
LIAROZOLE + Raloxifene
|
DCGTIC1
|
LIAROZOLE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
LIAROZOLE + Raloxifene
|
DCZRKZO
|
LIAROZOLE
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
LIAROZOLE + Raloxifene
|
DCF9TTC
|
LIAROZOLE
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
LIAROZOLE + Raloxifene
|
DC7YFSC
|
LIAROZOLE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
LIAROZOLE + Raloxifene
|
DCAA9PP
|
LIAROZOLE
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
LIAROZOLE + Raloxifene
|
DC8BII9
|
LIAROZOLE
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Mechlorethamine + Raloxifene
|
DCWF65T
|
Mechlorethamine
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Mechlorethamine + Raloxifene
|
DC0S7RW
|
Mechlorethamine
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Mechlorethamine + Raloxifene
|
DCVG2C6
|
Mechlorethamine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Mechlorethamine + Raloxifene
|
DCKE2FZ
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Mechlorethamine + Raloxifene
|
DCFTCEO
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Mechlorethamine + Raloxifene
|
DCXYBLK
|
Mechlorethamine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Mechlorethamine + Raloxifene
|
DCZ34EO
|
Mechlorethamine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Mechlorethamine + Raloxifene
|
DCFQ97O
|
Mechlorethamine
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Mechlorethamine + Raloxifene
|
DCLEX8Y
|
Mechlorethamine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Mechlorethamine + Raloxifene
|
DC01XLF
|
Mechlorethamine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Methotrexate + Raloxifene
|
DCLIDDT
|
Methotrexate
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Methotrexate + Raloxifene
|
DC20EJM
|
Methotrexate
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Methotrexate + Raloxifene
|
DCR6KUC
|
Methotrexate
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[2] |
|
Methotrexate + Raloxifene
|
DCAZI1W
|
Methotrexate
|
Melanoma (Cell Line: MALME-3M)
|
[2] |
|
Methotrexate + Raloxifene
|
DCMMTUY
|
Methotrexate
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Nilotinib + Raloxifene
|
DCXHXMC
|
Nilotinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Nilotinib + Raloxifene
|
DCSG3LL
|
Nilotinib
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Nilotinib + Raloxifene
|
DCY7BWN
|
Nilotinib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Nilotinib + Raloxifene
|
DCN8MUS
|
Nilotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Nilotinib + Raloxifene
|
DC5R34V
|
Nilotinib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Picoplatin + Raloxifene
|
DC75UHE
|
Picoplatin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Picoplatin + Raloxifene
|
DC2REMC
|
Picoplatin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Picoplatin + Raloxifene
|
DC1I9XN
|
Picoplatin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Picoplatin + Raloxifene
|
DCAJ4I8
|
Picoplatin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Picoplatin + Raloxifene
|
DCNEOM9
|
Picoplatin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Plicamycin + Raloxifene
|
DCHPQKH
|
Plicamycin
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Plicamycin + Raloxifene
|
DCHVZO7
|
Plicamycin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Plicamycin + Raloxifene
|
DCQ3KTO
|
Plicamycin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Mechlorethamine
|
DC6IJ0N
|
Mechlorethamine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Mechlorethamine
|
DCE8HTJ
|
Mechlorethamine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Mechlorethamine
|
DCZEW1H
|
Mechlorethamine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Pentostatin
|
DC57131
|
Pentostatin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + Pentostatin
|
DCJ5Q8U
|
Pentostatin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Fulvestrant
|
DCYVVEQ
|
Fulvestrant
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Fulvestrant
|
DCOA82U
|
Fulvestrant
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Fulvestrant
|
DCLQPFO
|
Fulvestrant
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Gefitinib
|
DCESDYO
|
Gefitinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Gefitinib
|
DCP0YXL
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Ruxolitinib
|
DC7BQDC
|
Ruxolitinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Ruxolitinib
|
DCEA411
|
Ruxolitinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Raloxifene + Ixabepilone
|
DCHLCJD
|
Ixabepilone
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + Ixabepilone
|
DC95LEU
|
Ixabepilone
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Ixabepilone
|
DC4PX4D
|
Ixabepilone
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Dactinomycin
|
DCVAEOF
|
Dactinomycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Dactinomycin
|
DCXZOFI
|
Dactinomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + DFN-15
|
DCV9PSZ
|
DFN-15
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + DFN-15
|
DC6CLI2
|
DFN-15
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Lapatinib
|
DCP5VLZ
|
Lapatinib
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Raloxifene + Lapatinib
|
DCY86KH
|
Lapatinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Lapatinib
|
DCQTDSM
|
Lapatinib
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Carfilzomib
|
DCYO0AS
|
Carfilzomib
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
Raloxifene + PMID28460551-Compound-2
|
DC3GWBQ
|
PMID28460551-Compound-2
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Cyclophosphamide
|
DCXLBJA
|
Cyclophosphamide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Cyclophosphamide
|
DCL7YXY
|
Cyclophosphamide
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Cyclophosphamide
|
DC1ORTZ
|
Cyclophosphamide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + LIAROZOLE
|
DCB3Q0B
|
LIAROZOLE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + LIAROZOLE
|
DCIXN92
|
LIAROZOLE
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + LIAROZOLE
|
DCIK2YJ
|
LIAROZOLE
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Vismodegib
|
DCXYRND
|
Vismodegib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Vismodegib
|
DCI5WC5
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Isoniazid
|
DCHETXK
|
Isoniazid
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Isoniazid
|
DCX7R54
|
Isoniazid
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Isoniazid
|
DCD805I
|
Isoniazid
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Arsenic trioxide
|
DCI4C4X
|
Arsenic trioxide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Arsenic trioxide
|
DCWX5UO
|
Arsenic trioxide
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Raloxifene + Arsenic trioxide
|
DCBV35L
|
Arsenic trioxide
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Vemurafenib
|
DC5AZDU
|
Vemurafenib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Vemurafenib
|
DC11K7H
|
Vemurafenib
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + Vemurafenib
|
DC5CH2C
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Vemurafenib
|
DCSGGQ3
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Raloxifene + Vemurafenib
|
DCBDJ6J
|
Vemurafenib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Fostamatinib
|
DCAQREV
|
Fostamatinib
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
Raloxifene + Plicamycin
|
DCUUWEB
|
Plicamycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + Plicamycin
|
DC0VRBE
|
Plicamycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Plicamycin
|
DC1HCMI
|
Plicamycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Plicamycin
|
DC09HHD
|
Plicamycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Plicamycin
|
DCC6K8Y
|
Plicamycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Plicamycin
|
DC22SQP
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Plicamycin
|
DC7TSFW
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Plicamycin
|
DCA7TFM
|
Plicamycin
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Raloxifene + Plicamycin
|
DCIK646
|
Plicamycin
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Raloxifene + Plicamycin
|
DCD9V8Q
|
Plicamycin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Plicamycin
|
DCYSBJ0
|
Plicamycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Plicamycin
|
DCOLUJ2
|
Plicamycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Raloxifene + Nilotinib
|
DCUHZFJ
|
Nilotinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Nilotinib
|
DC33ECZ
|
Nilotinib
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Raloxifene + Nilotinib
|
DCXECFR
|
Nilotinib
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Nilotinib
|
DC5G1RN
|
Nilotinib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Raloxifene + Nilotinib
|
DC6OSPL
|
Nilotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Thioguanine
|
DC2N1P9
|
Thioguanine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + Thioguanine
|
DC2L97W
|
Thioguanine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Thioguanine
|
DCJLQ54
|
Thioguanine
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Raloxifene + Thioguanine
|
DCN1GAV
|
Thioguanine
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + Thioguanine
|
DCLV1C1
|
Thioguanine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Thioguanine
|
DCBT6UY
|
Thioguanine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Thioguanine
|
DCUJ467
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Thioguanine
|
DC4P03U
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Raloxifene + Thioguanine
|
DCO82S6
|
Thioguanine
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Raloxifene + Thioguanine
|
DCCVYC9
|
Thioguanine
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Raloxifene + Thioguanine
|
DCVWYMS
|
Thioguanine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Raloxifene + Thioguanine
|
DCC8KZQ
|
Thioguanine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Raloxifene + Triapine
|
DCAMQ8S
|
Triapine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Triapine
|
DCMXBQZ
|
Triapine
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + ABIRATERONE
|
DC912R2
|
ABIRATERONE
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + ABIRATERONE
|
DCOQX8F
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + ABIRATERONE
|
DCGRV3P
|
ABIRATERONE
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + 10-hydroxycamptothecin
|
DC1L666
|
10-hydroxycamptothecin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Topetecan
|
DCJH9FQ
|
Topetecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Topetecan
|
DCJW8CD
|
Topetecan
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Topetecan
|
DCIGOI8
|
Topetecan
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Raloxifene + Amonafide
|
DC0O9B6
|
Amonafide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Amonafide
|
DCWDGT5
|
Amonafide
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Raloxifene + Pralatrexate
|
DCX5DCW
|
Pralatrexate
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Pralatrexate
|
DCRV0C0
|
Pralatrexate
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Pralatrexate
|
DCZ555U
|
Pralatrexate
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Pralatrexate
|
DCPLY02
|
Pralatrexate
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Raloxifene + Pralatrexate
|
DCSN6OH
|
Pralatrexate
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Cantharidin
|
DCVYTAP
|
Cantharidin
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
Raloxifene + Terameprocol
|
DCLIIMI
|
Terameprocol
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Terameprocol
|
DC973CU
|
Terameprocol
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + SCH 727965
|
DCHAV8B
|
SCH 727965
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + SCH 727965
|
DCQCVBT
|
SCH 727965
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Raloxifene + SCH 727965
|
DC9VJH2
|
SCH 727965
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + SCH 727965
|
DCQN83C
|
SCH 727965
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + SCH 727965
|
DCAF86N
|
SCH 727965
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + SCH 727965
|
DCEZP9H
|
SCH 727965
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Ifosfamide
|
DC67GNF
|
Ifosfamide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Ifosfamide
|
DCICGSU
|
Ifosfamide
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Ifosfamide
|
DCENSKS
|
Ifosfamide
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + Ifosfamide
|
DCPINZB
|
Ifosfamide
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Ifosfamide
|
DCR1KFH
|
Ifosfamide
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Ifosfamide
|
DCYHWRT
|
Ifosfamide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Ifosfamide
|
DC9Z621
|
Ifosfamide
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Ifosfamide
|
DCP8FIE
|
Ifosfamide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Palbociclib
|
DCJSXE4
|
Palbociclib
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
Raloxifene + Palbociclib
|
DC602ZD
|
Palbociclib
|
Primitive neuroectodermal tumor (Cell Line: TC-32)
|
[2] |
|
Raloxifene + Dexrazoxane
|
DCNZQ26
|
Dexrazoxane
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + Dexrazoxane
|
DCCI8AC
|
Dexrazoxane
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Dexrazoxane
|
DCA0YTG
|
Dexrazoxane
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Raloxifene + Docetaxel
|
DCNQHIQ
|
Docetaxel
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Docetaxel
|
DCTK32V
|
Docetaxel
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Raloxifene + Raloxifene
|
DC0P8W3
|
Raloxifene
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + Raloxifene
|
DCUQ2JS
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Raloxifene
|
DCPZIBS
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Raloxifene + Bendamustine hydrochloride
|
DC8B9O3
|
Bendamustine hydrochloride
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + Bendamustine hydrochloride
|
DCUCIMB
|
Bendamustine hydrochloride
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Bendamustine hydrochloride
|
DC2SRB3
|
Bendamustine hydrochloride
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Bendamustine hydrochloride
|
DCZ9IJD
|
Bendamustine hydrochloride
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Bendamustine hydrochloride
|
DCG0ONS
|
Bendamustine hydrochloride
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Sirolimus
|
DCE7071
|
Sirolimus
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Letrozole
|
DCFRLP5
|
Letrozole
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Letrozole
|
DC0KEEB
|
Letrozole
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Mitomycin
|
DCGS38Q
|
Mitomycin
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Raloxifene + Mitomycin
|
DCOKAVQ
|
Mitomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Mitomycin
|
DCFTRWW
|
Mitomycin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Uracil mustard
|
DCBZFEP
|
Uracil mustard
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Raloxifene + Vincristine
|
DCL7IJ4
|
Vincristine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Arfolitixorin
|
DC9HMBY
|
Arfolitixorin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + Arfolitixorin
|
DCDS7E0
|
Arfolitixorin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Arfolitixorin
|
DCE9FO4
|
Arfolitixorin
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Raloxifene + Arfolitixorin
|
DCW8948
|
Arfolitixorin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Arfolitixorin
|
DC106LX
|
Arfolitixorin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Arfolitixorin
|
DCDKTSR
|
Arfolitixorin
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Raloxifene + Arfolitixorin
|
DCCDVTU
|
Arfolitixorin
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Raloxifene + BIO-300
|
DCYE7ND
|
BIO-300
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + BIO-300
|
DCLW8SE
|
BIO-300
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + BIO-300
|
DC3CR0N
|
BIO-300
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Altretamine
|
DCHN6GP
|
Altretamine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Altretamine
|
DCL0S84
|
Altretamine
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + Altretamine
|
DCV83H2
|
Altretamine
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Raloxifene + Altretamine
|
DCWXPEI
|
Altretamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + AS602868
|
DC602F8
|
AS602868
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
Raloxifene + Dorsomorphin
|
DC68VCS
|
Dorsomorphin
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
Raloxifene + Dorsomorphin
|
DCA8TST
|
Dorsomorphin
|
Primitive neuroectodermal tumor (Cell Line: TC-32)
|
[2] |
|
Raloxifene + TEM
|
DCG43CY
|
TEM
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Raloxifene + TEM
|
DC0KG0L
|
TEM
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + TEM
|
DCWDEO8
|
TEM
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Raloxifene + TEM
|
DCED6J0
|
TEM
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Raloxifene + TEM
|
DCQUMVY
|
TEM
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Indazole derivative 5
|
DCUBDT0
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Indazole derivative 5
|
DCVKR3P
|
Indazole derivative 5
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Raloxifene + Indazole derivative 5
|
DCN2L01
|
Indazole derivative 5
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Raloxifene + Imatinib
|
DCRU5WM
|
Imatinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Imatinib
|
DCWKITW
|
Imatinib
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Raloxifene + Bleomycin
|
DCRJCUI
|
Bleomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Bleomycin
|
DCR6AF5
|
Bleomycin
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Raloxifene + Bortezomib
|
DCQ31GN
|
Bortezomib
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + Bortezomib
|
DC153OU
|
Bortezomib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Bortezomib
|
DCVRITC
|
Bortezomib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Anastrozole
|
DC4IHSO
|
Anastrozole
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + Anastrozole
|
DC2DGBT
|
Anastrozole
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Anastrozole
|
DC1IPYH
|
Anastrozole
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Dacarbazine
|
DC56KE5
|
Dacarbazine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Dacarbazine
|
DCRDW8Z
|
Dacarbazine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Dacarbazine
|
DC58BZV
|
Dacarbazine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Dacarbazine
|
DCX2F4M
|
Dacarbazine
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Dacarbazine
|
DCOKG4G
|
Dacarbazine
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Raloxifene + Valrubicin
|
DCG9RGZ
|
Valrubicin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + Valrubicin
|
DCXV013
|
Valrubicin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Valrubicin
|
DCPWVVP
|
Valrubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Valrubicin
|
DCKRW8Z
|
Valrubicin
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Raloxifene + Valrubicin
|
DCBAU5T
|
Valrubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Raloxifene + Valrubicin
|
DC1I160
|
Valrubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Topotecan
|
DC02ERB
|
Topotecan
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Topotecan
|
DCJK59J
|
Topotecan
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Raloxifene + Cabazitaxel
|
DCP10H3
|
Cabazitaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Epirubicin
|
DCISJ8Q
|
Epirubicin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Epirubicin
|
DCD3WUE
|
Epirubicin
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Raloxifene + Epirubicin
|
DC8H8MP
|
Epirubicin
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + Epirubicin
|
DC19IIG
|
Epirubicin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Epirubicin
|
DCIXE37
|
Epirubicin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Epirubicin
|
DCABI0R
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Epirubicin
|
DC2GHEO
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Epirubicin
|
DCNLRXG
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Raloxifene + Epirubicin
|
DCCUWXC
|
Epirubicin
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Epirubicin
|
DC8RR3G
|
Epirubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Raloxifene + Epirubicin
|
DCM3MWU
|
Epirubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + BMS-754807
|
DCF05DZ
|
BMS-754807
|
Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)
|
[2] |
|
Raloxifene + BMS-754807
|
DC9EWAV
|
BMS-754807
|
Primitive neuroectodermal tumor (Cell Line: TC-32)
|
[2] |
|
Raloxifene + Cisplatin
|
DCCY9RH
|
Cisplatin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Cisplatin
|
DC1787Y
|
Cisplatin
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + Cisplatin
|
DCE7HR8
|
Cisplatin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Cisplatin
|
DCSR8TQ
|
Cisplatin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Vandetanib
|
DCMIG0Z
|
Vandetanib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Chlorambucil
|
DCE4KE4
|
Chlorambucil
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Raloxifene + Chlorambucil
|
DCB4NKV
|
Chlorambucil
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Raloxifene + Chlorambucil
|
DCUKUEO
|
Chlorambucil
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Raloxifene + Sorafenib
|
DC4CICI
|
Sorafenib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + Sorafenib
|
DC3BX2T
|
Sorafenib
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Raloxifene + Sorafenib
|
DCVAT3M
|
Sorafenib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Sorafenib
|
DC42FA1
|
Sorafenib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Sorafenib
|
DC0QXXZ
|
Sorafenib
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Raloxifene + Sorafenib
|
DCB590L
|
Sorafenib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + ER819762
|
DC2VLTK
|
ER819762
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + ER819762
|
DCPN695
|
ER819762
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + ER819762
|
DC8I3LY
|
ER819762
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Raloxifene + ER819762
|
DCSWECQ
|
ER819762
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Raloxifene + ER819762
|
DCAUHFQ
|
ER819762
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Romidepsin
|
DCRTQSU
|
Romidepsin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Romidepsin
|
DCW41EI
|
Romidepsin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
Raloxifene + Azacitidine
|
DCJMF9T
|
Azacitidine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Azacitidine
|
DCBSCRL
|
Azacitidine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Azacitidine
|
DCRKKJD
|
Azacitidine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Raloxifene + Pomalidomide
|
DC7OJBA
|
Pomalidomide
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Raloxifene + Pomalidomide
|
DCA9YHQ
|
Pomalidomide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Pomalidomide
|
DCTL32V
|
Pomalidomide
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Raloxifene + Vinflunine
|
DCDGBKQ
|
Vinflunine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Vinflunine
|
DCMLH6X
|
Vinflunine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Mepacrine
|
DC6GCO8
|
Mepacrine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Mepacrine
|
DCEU50R
|
Mepacrine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + Mepacrine
|
DC6H61X
|
Mepacrine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + Mepacrine
|
DCQAS7X
|
Mepacrine
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Mepacrine
|
DCOB3WT
|
Mepacrine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Raloxifene + Mepacrine
|
DCW6XD1
|
Mepacrine
|
Glioma (Cell Line: SF-539)
|
[2] |
|
Raloxifene + Fludarabine
|
DCJR79O
|
Fludarabine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + Fludarabine
|
DC7QBKM
|
Fludarabine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCGAM3P
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: HT29)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCPA2RR
|
PMID28870136-Compound-43
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCGGABM
|
PMID28870136-Compound-43
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DC9I0W4
|
PMID28870136-Compound-43
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DC7JFKZ
|
PMID28870136-Compound-43
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCQ7KR7
|
PMID28870136-Compound-43
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCCLXZU
|
PMID28870136-Compound-43
|
Glioblastoma (Cell Line: SNB-75)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCXEKKP
|
PMID28870136-Compound-43
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
Raloxifene + PMID28870136-Compound-43
|
DCF0PR1
|
PMID28870136-Compound-43
|
Renal cell carcinoma (Cell Line: SN12C)
|
[2] |
|
Raloxifene + FORMESTANE
|
DCQRD2Y
|
FORMESTANE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + FORMESTANE
|
DCCGR6B
|
FORMESTANE
|
Astrocytoma (Cell Line: U251)
|
[2] |
|
Raloxifene + FORMESTANE
|
DC1VX47
|
FORMESTANE
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + FORMESTANE
|
DCUAT12
|
FORMESTANE
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Raloxifene + FORMESTANE
|
DCHHE7F
|
FORMESTANE
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Raloxifene + FORMESTANE
|
DCDN2V3
|
FORMESTANE
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + FORMESTANE
|
DCY8LAA
|
FORMESTANE
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Raloxifene + FORMESTANE
|
DCS1PIP
|
FORMESTANE
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Raloxifene + Aminolevulinic Acid Hydrochloride
|
DCE6P9R
|
Aminolevulinic Acid Hydrochloride
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Raloxifene + Estramustine
|
DC1FRDA
|
Estramustine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Raloxifene + Estramustine
|
DC8YI17
|
Estramustine
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + Estramustine
|
DCAP3RV
|
Estramustine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Raloxifene + Estramustine
|
DC2CIMU
|
Estramustine
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Estramustine
|
DC3QR83
|
Estramustine
|
Glioma (Cell Line: SF-295)
|
[2] |
|
Raloxifene + Busulfan
|
DCFW3Q4
|
Busulfan
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Raloxifene + Busulfan
|
DC0GBW1
|
Busulfan
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Raloxifene + Busulfan
|
DCZZYVX
|
Busulfan
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Raloxifene + Mechlorethamine
|
DCD0FK6
|
Mechlorethamine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Pentostatin
|
DCMVMYA
|
Pentostatin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Pentostatin
|
DCPLRVM
|
Pentostatin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Fulvestrant
|
DCIOFQF
|
Fulvestrant
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Fulvestrant
|
DCWN5VK
|
Fulvestrant
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Raloxifene + Fulvestrant
|
DCZLP8G
|
Fulvestrant
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Gefitinib
|
DCSYOMW
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Hepzato
|
DCLDZDY
|
Hepzato
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + Hepzato
|
DCAVXRW
|
Hepzato
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + DFN-15
|
DCHP3UL
|
DFN-15
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + DFN-15
|
DCGS5ZM
|
DFN-15
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Lapatinib
|
DCM1H40
|
Lapatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Raloxifene + Vismodegib
|
DCG5Y8E
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Isoniazid
|
DCQ9H2O
|
Isoniazid
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Raloxifene + Isoniazid
|
DCIITGW
|
Isoniazid
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Isoniazid
|
DC48WL3
|
Isoniazid
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Vemurafenib
|
DCKDU9U
|
Vemurafenib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Vemurafenib
|
DC1691S
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Vemurafenib
|
DC60Y8Z
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Plicamycin
|
DCZHEKG
|
Plicamycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + Plicamycin
|
DC51BBS
|
Plicamycin
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Raloxifene + Plicamycin
|
DCPFTMU
|
Plicamycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Plicamycin
|
DCBQOVE
|
Plicamycin
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Raloxifene + Plicamycin
|
DCIGNV8
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Plicamycin
|
DCCFFCC
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Nilotinib
|
DCENK9K
|
Nilotinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Nilotinib
|
DCAGSU3
|
Nilotinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Thioguanine
|
DCC2G6W
|
Thioguanine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + Thioguanine
|
DCI8OSF
|
Thioguanine
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Raloxifene + Thioguanine
|
DC2NRLP
|
Thioguanine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Triapine
|
DCY4SMU
|
Triapine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + ABIRATERONE
|
DCRGI3J
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + ABIRATERONE
|
DCB8E1W
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Topetecan
|
DCFWK7G
|
Topetecan
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Raloxifene + Pralatrexate
|
DCBU4N1
|
Pralatrexate
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Terameprocol
|
DCTZ0A3
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Terameprocol
|
DCWB715
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + SCH 727965
|
DCHA4GC
|
SCH 727965
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + SCH 727965
|
DC4MA4U
|
SCH 727965
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + SCH 727965
|
DCIMAS1
|
SCH 727965
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Raloxifene + SCH 727965
|
DCFE127
|
SCH 727965
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Ifosfamide
|
DCXDFBZ
|
Ifosfamide
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + Ifosfamide
|
DCLVL4O
|
Ifosfamide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Ifosfamide
|
DC9VYK9
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Dexrazoxane
|
DC39VR5
|
Dexrazoxane
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Raloxifene
|
DCQH3RW
|
Raloxifene
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Raloxifene + Sirolimus
|
DCD29OF
|
Sirolimus
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + Sirolimus
|
DCZRYFU
|
Sirolimus
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Raloxifene + Letrozole
|
DCRVIM4
|
Letrozole
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + Letrozole
|
DCGVBQD
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Letrozole
|
DCK2R7M
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Raloxifene + Letrozole
|
DC382EL
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Mitomycin
|
DCCF5WV
|
Mitomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Mitomycin
|
DCXPSUY
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Raloxifene + Arfolitixorin
|
DC1LYHF
|
Arfolitixorin
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Raloxifene + Arfolitixorin
|
DCQF9W8
|
Arfolitixorin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Altretamine
|
DCNGM0F
|
Altretamine
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Raloxifene + Altretamine
|
DC6Y397
|
Altretamine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Altretamine
|
DCXFVZT
|
Altretamine
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Raloxifene + TEM
|
DCF6RVK
|
TEM
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Raloxifene + TEM
|
DC1VYFU
|
TEM
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + TEM
|
DCX877Y
|
TEM
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Raloxifene + TEM
|
DCYGTWQ
|
TEM
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Idarubicin
|
DCDAD9A
|
Idarubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCH740C
|
Indazole derivative 5
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCAQVAP
|
Indazole derivative 5
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCUDB90
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCQ746K
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DC6AENR
|
Indazole derivative 5
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Bortezomib
|
DCV8AY3
|
Bortezomib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Anastrozole
|
DC0MM99
|
Anastrozole
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Dacarbazine
|
DC0CSRM
|
Dacarbazine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + Dacarbazine
|
DCAZSPV
|
Dacarbazine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Valrubicin
|
DCJIP3U
|
Valrubicin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + Valrubicin
|
DC3118Q
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Topotecan
|
DCRCO3H
|
Topotecan
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Epirubicin
|
DC6ISHY
|
Epirubicin
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Raloxifene + Epirubicin
|
DC5TED2
|
Epirubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Epirubicin
|
DC78E56
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Epirubicin
|
DCVG7XP
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Raloxifene + Epirubicin
|
DCCBAP2
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + Chlorambucil
|
DCGOMH4
|
Chlorambucil
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + ER819762
|
DCPQLY8
|
ER819762
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Azacitidine
|
DCVW4AA
|
Azacitidine
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Raloxifene + Pomalidomide
|
DC43O9I
|
Pomalidomide
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Raloxifene + Pomalidomide
|
DCE7BTT
|
Pomalidomide
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Vinflunine
|
DCQ0UOT
|
Vinflunine
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Raloxifene + Vinflunine
|
DC88PEB
|
Vinflunine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Raloxifene + Mepacrine
|
DCRZ2XR
|
Mepacrine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + Mepacrine
|
DCBD5UM
|
Mepacrine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Raloxifene + PMID28870136-Compound-43
|
DCCHNZ3
|
PMID28870136-Compound-43
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + FORMESTANE
|
DCPVCOJ
|
FORMESTANE
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Raloxifene + Estramustine
|
DC74B30
|
Estramustine
|
Carcinoma (Cell Line: RXF 393)
|
[3] |
|
Raloxifene + Dasatinib
|
DC6L404
|
Dasatinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Raloxifene + Dasatinib
|
DCCP3EJ
|
Dasatinib
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Raloxifene + Dasatinib
|
DC4Q2JL
|
Dasatinib
|
Colon carcinoma (Cell Line: KM12)
|
[3] |
|
Raloxifene + Mechlorethamine
|
DCFP32S
|
Mechlorethamine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Mechlorethamine
|
DCONXFB
|
Mechlorethamine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + Pentostatin
|
DCR2DUC
|
Pentostatin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Pentostatin
|
DCU8SVH
|
Pentostatin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + Pentostatin
|
DCTJLFC
|
Pentostatin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Pentostatin
|
DCBVE4A
|
Pentostatin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Pentostatin
|
DCBSK5F
|
Pentostatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Pentostatin
|
DCEEDM5
|
Pentostatin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + Pentostatin
|
DC0XB3Q
|
Pentostatin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Raloxifene + Picoplatin
|
DCABBO2
|
Picoplatin
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Fulvestrant
|
DCM8G02
|
Fulvestrant
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Fulvestrant
|
DC37295
|
Fulvestrant
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Fulvestrant
|
DCMO2A2
|
Fulvestrant
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Fulvestrant
|
DCFCRPU
|
Fulvestrant
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Fulvestrant
|
DCEMQKH
|
Fulvestrant
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + Fulvestrant
|
DCCW9KG
|
Fulvestrant
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Fulvestrant
|
DCIUHHM
|
Fulvestrant
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Raloxifene + Fulvestrant
|
DC857G6
|
Fulvestrant
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Gefitinib
|
DCMD1Z4
|
Gefitinib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Raloxifene + Gefitinib
|
DCXLYWH
|
Gefitinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Gefitinib
|
DCNNDYI
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Gefitinib
|
DCIK8IH
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Gefitinib
|
DC36PBP
|
Gefitinib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Ruxolitinib
|
DCVE39C
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Ruxolitinib
|
DC7NBH6
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Ruxolitinib
|
DC8ZEQ8
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Ruxolitinib
|
DC9DYXW
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Raloxifene + Ruxolitinib
|
DCXJ9RK
|
Ruxolitinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Ruxolitinib
|
DC65DRT
|
Ruxolitinib
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Ruxolitinib
|
DCE6LFB
|
Ruxolitinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Raloxifene + Ruxolitinib
|
DC4SVVR
|
Ruxolitinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Hepzato
|
DC6Q336
|
Hepzato
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Hepzato
|
DCR9SF8
|
Hepzato
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Raloxifene + Hepzato
|
DC8AUL3
|
Hepzato
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Hepzato
|
DC18NZU
|
Hepzato
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Hepzato
|
DCZM1JU
|
Hepzato
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Ixabepilone
|
DC1D8QY
|
Ixabepilone
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Ixabepilone
|
DCLCF5E
|
Ixabepilone
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Ixabepilone
|
DCKR99R
|
Ixabepilone
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Dactinomycin
|
DC2ILHI
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Dactinomycin
|
DCI3H7A
|
Dactinomycin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + Dactinomycin
|
DCJ2DBL
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Raloxifene + DFN-15
|
DCHVUNU
|
DFN-15
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Raloxifene + DFN-15
|
DCZY0QN
|
DFN-15
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + DFN-15
|
DC1D8VE
|
DFN-15
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + DFN-15
|
DCUFWXG
|
DFN-15
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Lapatinib
|
DCFYJ1D
|
Lapatinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Lapatinib
|
DCEG994
|
Lapatinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Lapatinib
|
DCK27DV
|
Lapatinib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Lapatinib
|
DCAU1OG
|
Lapatinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Lapatinib
|
DC0GOHU
|
Lapatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Lapatinib
|
DC36NLS
|
Lapatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Crizotinib
|
DCC42OQ
|
Crizotinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Cyclophosphamide
|
DCXRAX5
|
Cyclophosphamide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Cyclophosphamide
|
DCILEIN
|
Cyclophosphamide
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Cyclophosphamide
|
DCNXCRC
|
Cyclophosphamide
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + Cyclophosphamide
|
DCGR0VE
|
Cyclophosphamide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Cyclophosphamide
|
DCM5SJ4
|
Cyclophosphamide
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Raloxifene + LIAROZOLE
|
DCYFULL
|
LIAROZOLE
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + Methotrexate
|
DCUOI4U
|
Methotrexate
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Raloxifene + Vismodegib
|
DCZNZPP
|
Vismodegib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Vismodegib
|
DCEOVE3
|
Vismodegib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Vismodegib
|
DCJZ3UW
|
Vismodegib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Vismodegib
|
DCMXE2H
|
Vismodegib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Vismodegib
|
DC6ZGTO
|
Vismodegib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Raloxifene + Vismodegib
|
DC2MKCB
|
Vismodegib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Vismodegib
|
DCOBJRG
|
Vismodegib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Raloxifene + Isoniazid
|
DCIPOCD
|
Isoniazid
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Isoniazid
|
DCIR723
|
Isoniazid
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Isoniazid
|
DC7B9GT
|
Isoniazid
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Isoniazid
|
DCKTUDT
|
Isoniazid
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Isoniazid
|
DCM0TW6
|
Isoniazid
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Isoniazid
|
DC365LT
|
Isoniazid
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Isoniazid
|
DCPVJG7
|
Isoniazid
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Isoniazid
|
DC3WPMG
|
Isoniazid
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Raloxifene + Isoniazid
|
DCJZKW0
|
Isoniazid
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Vemurafenib
|
DCUKQIJ
|
Vemurafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Vemurafenib
|
DC8NNYZ
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Raloxifene + Vemurafenib
|
DCDV2YL
|
Vemurafenib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Vemurafenib
|
DCHIHXU
|
Vemurafenib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + Vemurafenib
|
DCIXX9Q
|
Vemurafenib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Vemurafenib
|
DCFW2DL
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Vemurafenib
|
DCQEVMU
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Raloxifene + Vemurafenib
|
DCACDAU
|
Vemurafenib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Vemurafenib
|
DCG5P4O
|
Vemurafenib
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Vemurafenib
|
DC9G6QX
|
Vemurafenib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Lenalidomide
|
DCMGRIM
|
Lenalidomide
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + Lenalidomide
|
DCOXF31
|
Lenalidomide
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Lenalidomide
|
DCNW8WZ
|
Lenalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Lenalidomide
|
DCMJ3QO
|
Lenalidomide
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Plicamycin
|
DCE8N9U
|
Plicamycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Plicamycin
|
DCUM9M6
|
Plicamycin
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Raloxifene + Plicamycin
|
DCOUZUT
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + Plicamycin
|
DC1D11H
|
Plicamycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Plicamycin
|
DCRYFOB
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Plicamycin
|
DC3GRGR
|
Plicamycin
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Raloxifene + Plicamycin
|
DCVAQVT
|
Plicamycin
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Plicamycin
|
DCXINQ3
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Plicamycin
|
DC1ABVZ
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Plicamycin
|
DCFPRDH
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Raloxifene + Plicamycin
|
DCAUQ1P
|
Plicamycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Plicamycin
|
DCDWJ9S
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + Plicamycin
|
DC544CQ
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Raloxifene + Plicamycin
|
DCFK2GI
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Raloxifene + Plicamycin
|
DCBYAET
|
Plicamycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Raloxifene + Plicamycin
|
DC0E3AZ
|
Plicamycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Plicamycin
|
DCXL4SY
|
Plicamycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Raloxifene + Plicamycin
|
DC10ZO1
|
Plicamycin
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Nilotinib
|
DCUA7KH
|
Nilotinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + Nilotinib
|
DCM5INF
|
Nilotinib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Nilotinib
|
DC4AXDA
|
Nilotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Nilotinib
|
DCCKI2O
|
Nilotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Raloxifene + Nilotinib
|
DC90X13
|
Nilotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Raloxifene + Nilotinib
|
DC658RO
|
Nilotinib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Nilotinib
|
DCBYV7G
|
Nilotinib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Raloxifene + Nilotinib
|
DCH5P9V
|
Nilotinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Nilotinib
|
DCB9XF2
|
Nilotinib
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Thioguanine
|
DC6JYMM
|
Thioguanine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Thioguanine
|
DCTC5DH
|
Thioguanine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + Thioguanine
|
DCXU1CP
|
Thioguanine
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Thioguanine
|
DC7FD0B
|
Thioguanine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Thioguanine
|
DC60A57
|
Thioguanine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Thioguanine
|
DCNYHU0
|
Thioguanine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + Thioguanine
|
DCNIUKH
|
Thioguanine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Raloxifene + Thioguanine
|
DCWHQNU
|
Thioguanine
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Triapine
|
DCZ5QOS
|
Triapine
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Triapine
|
DCUOD3T
|
Triapine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Triapine
|
DCL7LGQ
|
Triapine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Raloxifene + Triapine
|
DCV8XZW
|
Triapine
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Triapine
|
DCC9F9K
|
Triapine
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Triapine
|
DCE3CBN
|
Triapine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Raloxifene + ABIRATERONE
|
DCD8BQ5
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + ABIRATERONE
|
DCMT2AD
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + ABIRATERONE
|
DCRMYLN
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + ABIRATERONE
|
DC984Q1
|
ABIRATERONE
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + ABIRATERONE
|
DCTLHNA
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + ABIRATERONE
|
DCUFUBS
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + ABIRATERONE
|
DC2XQJD
|
ABIRATERONE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + ABIRATERONE
|
DC9PAV8
|
ABIRATERONE
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + ABIRATERONE
|
DCPCYMR
|
ABIRATERONE
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + ABIRATERONE
|
DC2IW26
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + ABIRATERONE
|
DCM2JTD
|
ABIRATERONE
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Topetecan
|
DC8XCYX
|
Topetecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Raloxifene + Pralatrexate
|
DCG2S95
|
Pralatrexate
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Pralatrexate
|
DCFD0IA
|
Pralatrexate
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Raloxifene + Pralatrexate
|
DCPSBI7
|
Pralatrexate
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Pralatrexate
|
DC0VXLQ
|
Pralatrexate
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Pralatrexate
|
DCI0ZVY
|
Pralatrexate
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Terameprocol
|
DCERFI9
|
Terameprocol
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Terameprocol
|
DCGUJFM
|
Terameprocol
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Terameprocol
|
DCI7WU6
|
Terameprocol
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Terameprocol
|
DCYKKU3
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Raloxifene + Terameprocol
|
DCNVX59
|
Terameprocol
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Terameprocol
|
DCNOVY2
|
Terameprocol
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + SCH 727965
|
DCQXSQ5
|
SCH 727965
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + SCH 727965
|
DCRXJSM
|
SCH 727965
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + SCH 727965
|
DC8ZMXU
|
SCH 727965
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + SCH 727965
|
DC61X86
|
SCH 727965
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Raloxifene + SCH 727965
|
DCR9X3C
|
SCH 727965
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Ifosfamide
|
DCIT81F
|
Ifosfamide
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Ifosfamide
|
DCG77E4
|
Ifosfamide
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + Ifosfamide
|
DC6RUXR
|
Ifosfamide
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Ifosfamide
|
DCQCYY8
|
Ifosfamide
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Ifosfamide
|
DCQPU55
|
Ifosfamide
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Raloxifene + Ifosfamide
|
DC1GM88
|
Ifosfamide
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + Ifosfamide
|
DCC63OX
|
Ifosfamide
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Ifosfamide
|
DCRKYDE
|
Ifosfamide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Ifosfamide
|
DCCOR2A
|
Ifosfamide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Ifosfamide
|
DC0OWKT
|
Ifosfamide
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Raloxifene + Ifosfamide
|
DCHO11L
|
Ifosfamide
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Ifosfamide
|
DCRLZ4X
|
Ifosfamide
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Ifosfamide
|
DC14ZJE
|
Ifosfamide
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Raloxifene + Ifosfamide
|
DCQ27RI
|
Ifosfamide
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Raloxifene + Ifosfamide
|
DC5QW4S
|
Ifosfamide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Raloxifene + Dexrazoxane
|
DCHAU3B
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Dexrazoxane
|
DC7J1JZ
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Dexrazoxane
|
DCH8K8Z
|
Dexrazoxane
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Docetaxel
|
DC4K947
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Raloxifene + Raloxifene
|
DCZKI1K
|
Raloxifene
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + Raloxifene
|
DCD0CAO
|
Raloxifene
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Raloxifene
|
DC9WFCB
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Raloxifene
|
DCFINVX
|
Raloxifene
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Raloxifene + Bendamustine hydrochloride
|
DCP7VZ5
|
Bendamustine hydrochloride
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Bendamustine hydrochloride
|
DCJP7GL
|
Bendamustine hydrochloride
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Letrozole
|
DCEMHVB
|
Letrozole
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Letrozole
|
DCBDMW4
|
Letrozole
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Letrozole
|
DCY3PYK
|
Letrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Letrozole
|
DCR6OGU
|
Letrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Letrozole
|
DCBQD3B
|
Letrozole
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Raloxifene + Letrozole
|
DC1PIW8
|
Letrozole
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Letrozole
|
DC8EQUV
|
Letrozole
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Mitomycin
|
DCR64HZ
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Mitomycin
|
DC3QMKQ
|
Mitomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + Mitomycin
|
DCMTRBY
|
Mitomycin
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Mitomycin
|
DCWJH3N
|
Mitomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Mitomycin
|
DCT5WSL
|
Mitomycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Mitomycin
|
DCV14UP
|
Mitomycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Raloxifene + SY-1425
|
DCDZ9EU
|
SY-1425
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + SY-1425
|
DCEN7W2
|
SY-1425
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Uracil mustard
|
DCXG0R5
|
Uracil mustard
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Vincristine
|
DC0NUL5
|
Vincristine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Arfolitixorin
|
DCDB265
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Arfolitixorin
|
DCW0XVO
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Raloxifene + Arfolitixorin
|
DCZUZOO
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + Arfolitixorin
|
DCN4VHF
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Arfolitixorin
|
DCCH5NV
|
Arfolitixorin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Raloxifene + Arfolitixorin
|
DCGXLDC
|
Arfolitixorin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Raloxifene + Arfolitixorin
|
DCZXX2S
|
Arfolitixorin
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + BIO-300
|
DCATXS1
|
BIO-300
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + BIO-300
|
DCPCXR9
|
BIO-300
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Altretamine
|
DCGZWYZ
|
Altretamine
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + Altretamine
|
DCZO1BB
|
Altretamine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Altretamine
|
DCBRHJW
|
Altretamine
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Altretamine
|
DCIJNIS
|
Altretamine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Raloxifene + TEM
|
DC4IYD7
|
TEM
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + TEM
|
DCIZ8SE
|
TEM
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + TEM
|
DC56MDP
|
TEM
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + TEM
|
DC7RDYV
|
TEM
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Raloxifene + TEM
|
DCPUUVE
|
TEM
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + TEM
|
DCLIT6X
|
TEM
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Raloxifene + TEM
|
DC40Y6C
|
TEM
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + TEM
|
DCOV55H
|
TEM
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + TEM
|
DC6KGS7
|
TEM
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + TEM
|
DC5PAP6
|
TEM
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Idarubicin
|
DCUZPTT
|
Idarubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + Idarubicin
|
DCPB59K
|
Idarubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCAZJNZ
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DC9LFMS
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCSWG3U
|
Indazole derivative 5
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCC5S9O
|
Indazole derivative 5
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCX3858
|
Indazole derivative 5
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCECULE
|
Indazole derivative 5
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCVZH0V
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCZJL9V
|
Indazole derivative 5
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCCO7YX
|
Indazole derivative 5
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCL3LLH
|
Indazole derivative 5
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCCMPW8
|
Indazole derivative 5
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCO0NIJ
|
Indazole derivative 5
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCO3YTC
|
Indazole derivative 5
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DC850Z8
|
Indazole derivative 5
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DC7E0J9
|
Indazole derivative 5
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Raloxifene + Indazole derivative 5
|
DCYNOA7
|
Indazole derivative 5
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Imatinib
|
DC8KK50
|
Imatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Bleomycin
|
DCWPU5U
|
Bleomycin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + Bleomycin
|
DCWUYXI
|
Bleomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Bleomycin
|
DCEXMNM
|
Bleomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Raloxifene + Bortezomib
|
DC52AQB
|
Bortezomib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Anastrozole
|
DC7L29B
|
Anastrozole
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Raloxifene + Anastrozole
|
DCWOJIR
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Anastrozole
|
DCWTQZX
|
Anastrozole
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Anastrozole
|
DCIZC6T
|
Anastrozole
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Anastrozole
|
DC4IX9A
|
Anastrozole
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Raloxifene + Dacarbazine
|
DCGSX4G
|
Dacarbazine
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Dacarbazine
|
DC9JOT9
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Dacarbazine
|
DCSC5TV
|
Dacarbazine
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Dacarbazine
|
DCDSB2G
|
Dacarbazine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Dacarbazine
|
DC89T1V
|
Dacarbazine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Dacarbazine
|
DC0YTEI
|
Dacarbazine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Raloxifene + Dacarbazine
|
DC5C6L8
|
Dacarbazine
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Dacarbazine
|
DCI9COQ
|
Dacarbazine
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Valrubicin
|
DC4U32T
|
Valrubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Valrubicin
|
DCBH3W9
|
Valrubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Valrubicin
|
DCB9HVG
|
Valrubicin
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + Valrubicin
|
DCTXJB4
|
Valrubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Valrubicin
|
DC0ZEVL
|
Valrubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Valrubicin
|
DC4I2F5
|
Valrubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Valrubicin
|
DCUI8I6
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Raloxifene + Valrubicin
|
DCPCSPW
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + Valrubicin
|
DC2YD9F
|
Valrubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Valrubicin
|
DC0TDVV
|
Valrubicin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Valrubicin
|
DCNN0YK
|
Valrubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Topotecan
|
DCL09U6
|
Topotecan
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Topotecan
|
DC1XPJV
|
Topotecan
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Topotecan
|
DCFJZN2
|
Topotecan
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Topotecan
|
DCY1R5F
|
Topotecan
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Topotecan
|
DCMHJ22
|
Topotecan
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + Topotecan
|
DCULWHT
|
Topotecan
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Topotecan
|
DC1GRUD
|
Topotecan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Raloxifene + Topotecan
|
DCF0OTT
|
Topotecan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Topotecan
|
DC7FY87
|
Topotecan
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Topotecan
|
DCJYOZ9
|
Topotecan
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Topotecan
|
DC2DJBB
|
Topotecan
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Raloxifene + Topotecan
|
DCCLW61
|
Topotecan
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Cabazitaxel
|
DCGILC1
|
Cabazitaxel
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Raloxifene + Epirubicin
|
DCU5FHC
|
Epirubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Epirubicin
|
DCTB825
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Raloxifene + Epirubicin
|
DCU07RQ
|
Epirubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Epirubicin
|
DC4H0ZR
|
Epirubicin
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Raloxifene + Epirubicin
|
DCLHA8D
|
Epirubicin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Epirubicin
|
DCVFRMR
|
Epirubicin
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Epirubicin
|
DC26C0L
|
Epirubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Epirubicin
|
DC9987P
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Epirubicin
|
DCFCVX6
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Epirubicin
|
DC7OLWZ
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Epirubicin
|
DCV3HX5
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Epirubicin
|
DCS0D8A
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Raloxifene + Epirubicin
|
DCCVQCF
|
Epirubicin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Epirubicin
|
DCGQE06
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Raloxifene + Epirubicin
|
DCMMPZF
|
Epirubicin
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Epirubicin
|
DC36LNN
|
Epirubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Epirubicin
|
DC11CQ8
|
Epirubicin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Epirubicin
|
DCL9J1V
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Epirubicin
|
DC721N3
|
Epirubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Raloxifene + Epirubicin
|
DCPMI71
|
Epirubicin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Raloxifene + Epirubicin
|
DCDNCIA
|
Epirubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Raloxifene + Epirubicin
|
DC6YN7E
|
Epirubicin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Raloxifene + Epirubicin
|
DCVBALQ
|
Epirubicin
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Cisplatin
|
DC39PV6
|
Cisplatin
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Cisplatin
|
DCYFZR8
|
Cisplatin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Cisplatin
|
DCTDU7A
|
Cisplatin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Cisplatin
|
DC342XH
|
Cisplatin
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Cisplatin
|
DCR6UDU
|
Cisplatin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Raloxifene + Vandetanib
|
DCGVGDH
|
Vandetanib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Vandetanib
|
DCULBK8
|
Vandetanib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Vandetanib
|
DCE6XO2
|
Vandetanib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Chlorambucil
|
DCD0K7C
|
Chlorambucil
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Chlorambucil
|
DC5QGL6
|
Chlorambucil
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Chlorambucil
|
DC3YR8Q
|
Chlorambucil
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Raloxifene + Chlorambucil
|
DC02QSM
|
Chlorambucil
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Chlorambucil
|
DCFZEGY
|
Chlorambucil
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + Chlorambucil
|
DCBT3W2
|
Chlorambucil
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Chlorambucil
|
DCC3ITE
|
Chlorambucil
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Sorafenib
|
DCLWKIL
|
Sorafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Sorafenib
|
DC71ZM8
|
Sorafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Sorafenib
|
DC14E7I
|
Sorafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + ER819762
|
DC8B5WN
|
ER819762
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + ER819762
|
DCDPQZ9
|
ER819762
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Raloxifene + ER819762
|
DCEIQ1U
|
ER819762
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + ER819762
|
DCDM6KU
|
ER819762
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + ER819762
|
DC6PWO1
|
ER819762
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + ER819762
|
DCW8OF9
|
ER819762
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + ER819762
|
DCPX0Q8
|
ER819762
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + ER819762
|
DCBVQCK
|
ER819762
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + ER819762
|
DC5X0S0
|
ER819762
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + ER819762
|
DCC30EM
|
ER819762
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Raloxifene + ER819762
|
DCZ9LEM
|
ER819762
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Azacitidine
|
DCE7H8N
|
Azacitidine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Azacitidine
|
DCD0HY4
|
Azacitidine
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Azacitidine
|
DCM4GST
|
Azacitidine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Azacitidine
|
DCT69HE
|
Azacitidine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Raloxifene + Azacitidine
|
DCLXZZV
|
Azacitidine
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCIAA8I
|
Pomalidomide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCBV8LG
|
Pomalidomide
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCUFA56
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + Pomalidomide
|
DC2JEWK
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + Pomalidomide
|
DC9K3KL
|
Pomalidomide
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCGLUSG
|
Pomalidomide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Pomalidomide
|
DC62DGX
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCU9DD4
|
Pomalidomide
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCSJ0J0
|
Pomalidomide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + Pomalidomide
|
DC9HAYX
|
Pomalidomide
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Raloxifene + Pomalidomide
|
DC13ODB
|
Pomalidomide
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCMNOYL
|
Pomalidomide
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCED0E0
|
Pomalidomide
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCUBCMP
|
Pomalidomide
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCS8LI1
|
Pomalidomide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Raloxifene + Pomalidomide
|
DCLGWKH
|
Pomalidomide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Raloxifene + Vinflunine
|
DCZZVXS
|
Vinflunine
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Vinflunine
|
DCRRYLO
|
Vinflunine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Raloxifene + Vinflunine
|
DCMXXGM
|
Vinflunine
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + Vinflunine
|
DC71EVC
|
Vinflunine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Raloxifene + Vinflunine
|
DC6CVU3
|
Vinflunine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Raloxifene + Vinflunine
|
DCR43SK
|
Vinflunine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + Mepacrine
|
DCH30QU
|
Mepacrine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DCDBQO2
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DC5XXLL
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DC8EKGD
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DC49KEI
|
PMID28870136-Compound-43
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DCZ01W4
|
PMID28870136-Compound-43
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DCYQSKW
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DCCBF3W
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DCG7Q5R
|
PMID28870136-Compound-43
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DCMZ0DZ
|
PMID28870136-Compound-43
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DCRNRGI
|
PMID28870136-Compound-43
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DC8JKDH
|
PMID28870136-Compound-43
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DCKU4G0
|
PMID28870136-Compound-43
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DCMFEXN
|
PMID28870136-Compound-43
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Raloxifene + PMID28870136-Compound-43
|
DCYMP1W
|
PMID28870136-Compound-43
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCXZ1BI
|
FORMESTANE
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCPIVDO
|
FORMESTANE
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Raloxifene + FORMESTANE
|
DC49AGS
|
FORMESTANE
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCYAIBA
|
FORMESTANE
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Raloxifene + FORMESTANE
|
DC1XSPQ
|
FORMESTANE
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Raloxifene + FORMESTANE
|
DC2LU63
|
FORMESTANE
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCQEQF6
|
FORMESTANE
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + FORMESTANE
|
DC1YPOS
|
FORMESTANE
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCT91SE
|
FORMESTANE
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCIUHQJ
|
FORMESTANE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCD213X
|
FORMESTANE
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Raloxifene + FORMESTANE
|
DC4IUXQ
|
FORMESTANE
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Raloxifene + FORMESTANE
|
DCYID7W
|
FORMESTANE
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Raloxifene + FORMESTANE
|
DC599BF
|
FORMESTANE
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Aminolevulinic Acid Hydrochloride
|
DC3IB8N
|
Aminolevulinic Acid Hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Raloxifene + Aminolevulinic Acid Hydrochloride
|
DC6GS5L
|
Aminolevulinic Acid Hydrochloride
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + Aminolevulinic Acid Hydrochloride
|
DCVO5JS
|
Aminolevulinic Acid Hydrochloride
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Raloxifene + Aminolevulinic Acid Hydrochloride
|
DCJN0IG
|
Aminolevulinic Acid Hydrochloride
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Raloxifene + Estramustine
|
DCXQTM2
|
Estramustine
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Raloxifene + Estramustine
|
DC7IJC6
|
Estramustine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Raloxifene + Estramustine
|
DCL3IAM
|
Estramustine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Raloxifene + Estramustine
|
DCTL2FL
|
Estramustine
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Raloxifene + Estramustine
|
DCDGURV
|
Estramustine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Raloxifene + Estramustine
|
DCQGH82
|
Estramustine
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Raloxifene + Estramustine
|
DCIIFU2
|
Estramustine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[4] |
|
Raloxifene + Busulfan
|
DCHBCJZ
|
Busulfan
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Raloxifene + Dasatinib
|
DCM91KE
|
Dasatinib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Raloxifene + Dasatinib
|
DCMR2M2
|
Dasatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCOTO11
|
Ruxolitinib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Ruxolitinib + Raloxifene
|
DCTP4ZN
|
Ruxolitinib
|
Astrocytoma (Cell Line: SNB-19)
|
[2] |
|
Ruxolitinib + Raloxifene
|
DCOBSOR
|
Ruxolitinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Ruxolitinib + Raloxifene
|
DCZROOJ
|
Ruxolitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[2] |
|
Ruxolitinib + Raloxifene
|
DCHFQ5Q
|
Ruxolitinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[2] |
|
Ruxolitinib + Raloxifene
|
DCH922I
|
Ruxolitinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[2] |
|
Ruxolitinib + Raloxifene
|
DCGT9LJ
|
Ruxolitinib
|
Glioma (Cell Line: SF-268)
|
[2] |
|
Ruxolitinib + Raloxifene
|
DCR0R09
|
Ruxolitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Ruxolitinib + Raloxifene
|
DCXKYX3
|
Ruxolitinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Ruxolitinib + Raloxifene
|
DC0HZ18
|
Ruxolitinib
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Ruxolitinib + Raloxifene
|
DCT2VYQ
|
Ruxolitinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Ruxolitinib + Raloxifene
|
DC2G93W
|
Ruxolitinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Ruxolitinib + Raloxifene
|
DCFWM6F
|
Ruxolitinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Ruxolitinib + Raloxifene
|
DCIZZ0L
|
Ruxolitinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Ruxolitinib + Raloxifene
|
DC11GQL
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCPJTY0
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DC51BJE
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DC69E61
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCUUP3Q
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCLF6EQ
|
Ruxolitinib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCYYI57
|
Ruxolitinib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCQPWGD
|
Ruxolitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCTGWFL
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCSY3J1
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCSB9M1
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DC9E9UT
|
Ruxolitinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCB3RQ8
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCWGVPY
|
Ruxolitinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCP7V3S
|
Ruxolitinib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCQEJ1M
|
Ruxolitinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Ruxolitinib + Raloxifene
|
DCO22EP
|
Ruxolitinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
SY-1425 + Raloxifene
|
DC8PN8V
|
SY-1425
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
SY-1425 + Raloxifene
|
DCCHBKU
|
SY-1425
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[2] |
|
SY-1425 + Raloxifene
|
DCRQ2L8
|
SY-1425
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
SY-1425 + Raloxifene
|
DCW9GMN
|
SY-1425
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
SY-1425 + Raloxifene
|
DCPVXJ6
|
SY-1425
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Terameprocol + Raloxifene
|
DCMDNPU
|
Terameprocol
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[2] |
|
Terameprocol + Raloxifene
|
DCP6HCQ
|
Terameprocol
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Thioguanine + Raloxifene
|
DCNM9OV
|
Thioguanine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Thioguanine + Raloxifene
|
DCF7YZE
|
Thioguanine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Thioguanine + Raloxifene
|
DCZSRL6
|
Thioguanine
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Thioguanine + Raloxifene
|
DCUH0WK
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Thioguanine + Raloxifene
|
DCTXREW
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[2] |
|
Thioguanine + Raloxifene
|
DCZBTW6
|
Thioguanine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Thioguanine + Raloxifene
|
DCV72BJ
|
Thioguanine
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Thioguanine + Raloxifene
|
DCOW43O
|
Thioguanine
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Topotecan + Raloxifene
|
DC3QFJ1
|
Topotecan
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Triapine + Raloxifene
|
DC83WGN
|
Triapine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Triapine + Raloxifene
|
DCDE6SL
|
Triapine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Triapine + Raloxifene
|
DCL50BP
|
Triapine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Triapine + Raloxifene
|
DC2QIRL
|
Triapine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Triapine + Raloxifene
|
DCX67D4
|
Triapine
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Trifluridine + Raloxifene
|
DCIY7BJ
|
Trifluridine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Trifluridine + Raloxifene
|
DCEL76M
|
Trifluridine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Uracil mustard + Raloxifene
|
DCZPGXL
|
Uracil mustard
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Uracil mustard + Raloxifene
|
DCG71XR
|
Uracil mustard
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Uracil mustard + Raloxifene
|
DCBQOMW
|
Uracil mustard
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[2] |
|
Vandetanib + Raloxifene
|
DCVYXDD
|
Vandetanib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Vandetanib + Raloxifene
|
DCEE2LU
|
Vandetanib
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Vandetanib + Raloxifene
|
DCKH37N
|
Vandetanib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Vandetanib + Raloxifene
|
DC64N34
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Vandetanib + Raloxifene
|
DCNRGWE
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Vandetanib + Raloxifene
|
DCOZNSN
|
Vandetanib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Vandetanib + Raloxifene
|
DCI11V7
|
Vandetanib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Vandetanib + Raloxifene
|
DCA0K7Q
|
Vandetanib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Vandetanib + Raloxifene
|
DCJMAXD
|
Vandetanib
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[4] |
|
Vandetanib + Raloxifene
|
DC0KNX7
|
Vandetanib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Vandetanib + Raloxifene
|
DCQTURI
|
Vandetanib
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Vandetanib + Raloxifene
|
DC2JVUW
|
Vandetanib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Vandetanib + Raloxifene
|
DCUHO7R
|
Vandetanib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Vandetanib + Raloxifene
|
DCHZQCY
|
Vandetanib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Vandetanib + Raloxifene
|
DCSPHPX
|
Vandetanib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Vandetanib + Raloxifene
|
DC8C86D
|
Vandetanib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Vandetanib + Raloxifene
|
DCSI7S2
|
Vandetanib
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Vandetanib + Raloxifene
|
DCDHSZV
|
Vandetanib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Vandetanib + Raloxifene
|
DCFS31C
|
Vandetanib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Vandetanib + Raloxifene
|
DC8P00M
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Vandetanib + Raloxifene
|
DCAR30Y
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Vandetanib + Raloxifene
|
DCSHOF8
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Vandetanib + Raloxifene
|
DCHTIKL
|
Vandetanib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Vandetanib + Raloxifene
|
DC8WOE4
|
Vandetanib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Vandetanib + Raloxifene
|
DCJ2A28
|
Vandetanib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Vandetanib + Raloxifene
|
DC87WQD
|
Vandetanib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Vandetanib + Raloxifene
|
DCZ3KAU
|
Vandetanib
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Vandetanib + Raloxifene
|
DCBQVWI
|
Vandetanib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Vandetanib + Raloxifene
|
DCO1LRA
|
Vandetanib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Vandetanib + Raloxifene
|
DCFS4UA
|
Vandetanib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Vandetanib + Raloxifene
|
DCQA3ZR
|
Vandetanib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Vandetanib + Raloxifene
|
DC7LA5I
|
Vandetanib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCNY104
|
Vemurafenib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCOMO3U
|
Vemurafenib
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Vemurafenib + Raloxifene
|
DC8II47
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCIZAED
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCVO64L
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[3] |
|
Vemurafenib + Raloxifene
|
DCT21A4
|
Vemurafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCMEGOI
|
Vemurafenib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCSM29I
|
Vemurafenib
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCU59AE
|
Vemurafenib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC37E6D
|
Vemurafenib
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCP38FI
|
Vemurafenib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCS3DOS
|
Vemurafenib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCRR70K
|
Vemurafenib
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCO73N6
|
Vemurafenib
|
Glioma (Cell Line: SF-539)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCSVOSO
|
Vemurafenib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCOKXJM
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCAPZ67
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC9RZS7
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC8FJB0
|
Vemurafenib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC5ERI8
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCBJ5J9
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC683PV
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCI6IDY
|
Vemurafenib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCUSHKP
|
Vemurafenib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC9RYK0
|
Vemurafenib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC6GNXZ
|
Vemurafenib
|
Melanoma (Cell Line: MALME-3M)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCGAX2H
|
Vemurafenib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC6JHES
|
Vemurafenib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCY95VW
|
Vemurafenib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC9QB02
|
Vemurafenib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCEAIH5
|
Vemurafenib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Vemurafenib + Raloxifene
|
DCA7WKK
|
Vemurafenib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC9SLJS
|
Vemurafenib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Vemurafenib + Raloxifene
|
DC1Z0UZ
|
Vemurafenib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
|
Vincristine + Raloxifene
|
DCQ0DUX
|
Vincristine
|
Adenocarcinoma (Cell Line: DU-145)
|
[2] |
|
Vincristine + Raloxifene
|
DCOR1JK
|
Vincristine
|
Adenocarcinoma (Cell Line: HCT116)
|
[2] |
|
Vincristine + Raloxifene
|
DC2179Q
|
Vincristine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[2] |
|
Vincristine + Raloxifene
|
DCFRF7E
|
Vincristine
|
Amelanotic melanoma (Cell Line: M14)
|
[2] |
|
Vincristine + Raloxifene
|
DCPLM1E
|
Vincristine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[2] |
|
Vincristine + Raloxifene
|
DC8AY3T
|
Vincristine
|
Malignant melanoma (Cell Line: UACC62)
|
[2] |
|
Vincristine + Raloxifene
|
DCNUL93
|
Vincristine
|
Prostate carcinoma (Cell Line: PC-3)
|
[2] |
|
Vinflunine + Raloxifene
|
DCCM1PW
|
Vinflunine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[2] |
|
Vinflunine + Raloxifene
|
DC91W9S
|
Vinflunine
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[2] |
|
Vinflunine + Raloxifene
|
DCDPAM9
|
Vinflunine
|
Renal cell carcinoma (Cell Line: UO-31)
|
[2] |
|
Vinflunine + Raloxifene
|
DC8X7ZZ
|
Vinflunine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Vinflunine + Raloxifene
|
DC9WCTJ
|
Vinflunine
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Vinflunine + Raloxifene
|
DCRO588
|
Vinflunine
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Vinflunine + Raloxifene
|
DCAFOJI
|
Vinflunine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[4] |
|
Vinflunine + Raloxifene
|
DCL32QO
|
Vinflunine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Vinflunine + Raloxifene
|
DCUMV1Q
|
Vinflunine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Vinflunine + Raloxifene
|
DCBY9MG
|
Vinflunine
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Vismodegib + Raloxifene
|
DCBCZD3
|
Vismodegib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[3] |
|
Vismodegib + Raloxifene
|
DCGGPPD
|
Vismodegib
|
Carcinoma (Cell Line: MCF7)
|
[3] |
|
Vismodegib + Raloxifene
|
DCXMNUW
|
Vismodegib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[3] |
|
Vismodegib + Raloxifene
|
DC8B011
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[3] |
|
Vismodegib + Raloxifene
|
DCTITBA
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[3] |
|
Vismodegib + Raloxifene
|
DC8V720
|
Vismodegib
|
Adenocarcinoma (Cell Line: DU-145)
|
[4] |
|
Vismodegib + Raloxifene
|
DCBAFHM
|
Vismodegib
|
Adenocarcinoma (Cell Line: A549)
|
[4] |
|
Vismodegib + Raloxifene
|
DCSCZH7
|
Vismodegib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[4] |
|
Vismodegib + Raloxifene
|
DCG5V75
|
Vismodegib
|
Adenocarcinoma (Cell Line: SW-620)
|
[4] |
|
Vismodegib + Raloxifene
|
DCKPC7T
|
Vismodegib
|
Adenocarcinoma (Cell Line: HT29)
|
[4] |
|
Vismodegib + Raloxifene
|
DCV5R1K
|
Vismodegib
|
Adenocarcinoma (Cell Line: HCT116)
|
[4] |
|
Vismodegib + Raloxifene
|
DCSX4OW
|
Vismodegib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[4] |
|
Vismodegib + Raloxifene
|
DC960LC
|
Vismodegib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[4] |
|
Vismodegib + Raloxifene
|
DCR7X9Q
|
Vismodegib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[4] |
|
Vismodegib + Raloxifene
|
DC28RZ5
|
Vismodegib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[4] |
|
Vismodegib + Raloxifene
|
DCV4KHG
|
Vismodegib
|
Amelanotic melanoma (Cell Line: M14)
|
[4] |
|
Vismodegib + Raloxifene
|
DCPKD6X
|
Vismodegib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[4] |
|
Vismodegib + Raloxifene
|
DCNP3A0
|
Vismodegib
|
Astrocytoma (Cell Line: SNB-19)
|
[4] |
|
Vismodegib + Raloxifene
|
DCJAZ2Y
|
Vismodegib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[4] |
|
Vismodegib + Raloxifene
|
DC5ZJIR
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[4] |
|
Vismodegib + Raloxifene
|
DCQXTVS
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[4] |
|
Vismodegib + Raloxifene
|
DCQ3FQ3
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[4] |
|
Vismodegib + Raloxifene
|
DCSMVRE
|
Vismodegib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[4] |
|
Vismodegib + Raloxifene
|
DCMQF10
|
Vismodegib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[4] |
|
Vismodegib + Raloxifene
|
DCAXJ0Z
|
Vismodegib
|
Glioblastoma (Cell Line: SNB-75)
|
[4] |
|
Vismodegib + Raloxifene
|
DCPWZBB
|
Vismodegib
|
Glioma (Cell Line: SF-268)
|
[4] |
|
Vismodegib + Raloxifene
|
DC2HHUV
|
Vismodegib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[4] |
|
Vismodegib + Raloxifene
|
DC9PTAM
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[4] |
|
Vismodegib + Raloxifene
|
DCG6YC0
|
Vismodegib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[4] |
|
Vismodegib + Raloxifene
|
DC5MM1J
|
Vismodegib
|
Malignant melanoma (Cell Line: UACC62)
|
[4] |
|
Vismodegib + Raloxifene
|
DCDZG8W
|
Vismodegib
|
Melanoma (Cell Line: SK-MEL-2)
|
[4] |
|
Vismodegib + Raloxifene
|
DC7XWM3
|
Vismodegib
|
Melanoma (Cell Line: UACC-257)
|
[4] |
|
Vismodegib + Raloxifene
|
DC9GDB8
|
Vismodegib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[4] |
|
Vismodegib + Raloxifene
|
DCYJ8OD
|
Vismodegib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[4] |
|
Vismodegib + Raloxifene
|
DCN2BW1
|
Vismodegib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[4] |
|
Vismodegib + Raloxifene
|
DCQ8S3Y
|
Vismodegib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[4] |
|
Vismodegib + Raloxifene
|
DCEEDQU
|
Vismodegib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[4] |
|
Vismodegib + Raloxifene
|
DC2ZA3T
|
Vismodegib
|
Prostate carcinoma (Cell Line: PC-3)
|
[4] |
|
Vismodegib + Raloxifene
|
DCZ667K
|
Vismodegib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[4] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
